<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02515305</url>
  </required_header>
  <id_info>
    <org_study_id>PRG-NY-15-003</org_study_id>
    <nct_id>NCT02515305</nct_id>
  </id_info>
  <brief_title>Comparative Safety and Efficacy of Two Treatments in the Treatment of Acne Vulgaris</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Padagis LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Padagis LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and efficacy of Perrigo's product to an&#xD;
      FDA approved product for the treatment acne vulgaris&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Percent Change From Baseline in Inflammatory (Papules and Pustules) Lesions</measure>
    <time_frame>Baseline to Day 84</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Percent Change From Baseline in Non-inflammatory (Open and Closed Comedones) Lesions</measure>
    <time_frame>Baseline to Day 84</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">890</enrollment>
  <condition>Acne</condition>
  <arm_group>
    <arm_group_label>Test product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference product</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo product</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clindamycin and Benzoyl Peroxide Gel (combination)</intervention_name>
    <arm_group_label>Test product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clindamycin and Benzoyl Peroxide Gel (Reference) (combination)</intervention_name>
    <arm_group_label>Reference product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo gel (combination)</intervention_name>
    <arm_group_label>Placebo product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provide written informed consent/assent&#xD;
&#xD;
          2. Healthy male or non-pregnant females, 12 to 40 years of age, inclusive&#xD;
&#xD;
          3. Definite clinical diagnosis of acne vulgaris with an inflammatory lesion (papules and&#xD;
             pustules) count between 20 and 50 and a non-inflammatory (open and closed comedones)&#xD;
             lesion count between 25 and 100 and no more than 2 nodulocystic lesions (i.e., nodules&#xD;
             and cysts) including those present on the nose.&#xD;
&#xD;
          4. Baseline IGA score of 3 or 4 on a scale of 0 to 4.&#xD;
&#xD;
          5. Willing and able to understand and comply with the requirements of the study, apply&#xD;
             the medication as instructed, refrain from use of all other topical acne medication or&#xD;
             topical antibiotics during the 12-week treatment period, return for the required&#xD;
             treatment period visits, comply with therapy prohibitions, and are able to complete&#xD;
             the study.&#xD;
&#xD;
          6. Be in general good health and free from any clinically significant disease, other than&#xD;
             acne vulgaris, that might interfere with the study evaluations.&#xD;
&#xD;
          7. Females of childbearing potential willing to use an acceptable form of birth control&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Females who are pregnant, nursing, or planning a pregnancy within the study&#xD;
             participation period&#xD;
&#xD;
          2. More than 2 facial nodulocystic lesions (i.e. nodules and cysts).&#xD;
&#xD;
          3. Acne conglobata, acne fulminans, or secondary acne (chloracne, drug-induced acne,&#xD;
             etc.).&#xD;
&#xD;
          4. Active cystic acne or Polycystic Ovarian Syndrome.&#xD;
&#xD;
          5. History or presence of Crohn's disease, ulcerative colitis, regional enteritis,&#xD;
             inflammatory bowel disease, pseudomembranous colitis, chronic or recurrent diarrhea or&#xD;
             antibiotic-associated colitis.&#xD;
&#xD;
          6. Use of neuromuscular blocking agents (nondepolarizing agents and depolarizing agents)&#xD;
             Subjects who have had general anesthesia for any reason and subjects who have received&#xD;
             neuromuscular blocking agents within 14 days prior to study entry will be excluded&#xD;
             from study participation.&#xD;
&#xD;
          7. Presence of any other facial skin condition that might interfere with acne vulgaris&#xD;
             diagnosis and/or assessment (e.g., on the face: rosacea, dermatitis, psoriasis,&#xD;
             squamous cell carcinoma, eczema, acneform eruptions caused by medications, steroid&#xD;
             acne, steroid folliculitis, sunburn or bacterial folliculitis).&#xD;
&#xD;
          8. Excessive facial hair (e.g. beards, sideburns, moustaches, etc.) that would interfere&#xD;
             with diagnosis or assessment of acne vulgaris.&#xD;
&#xD;
          9. History of unresponsiveness to topical Clindamycin Phosphate and/or benzoyl peroxide&#xD;
             therapy.&#xD;
&#xD;
         10. Use of systemic Clindamycin products 4 weeks (30 days) prior to baseline or throughout&#xD;
             the study.&#xD;
&#xD;
         11. History of hypersensitivity or allergy to Clindamycin Phosphate, benzoyl peroxide&#xD;
             and/or any ingredient in the study medication.&#xD;
&#xD;
         12. Use within 6 months (180 days) prior to baseline or during the study of oral retinoids&#xD;
             (e.g. Accutane®) or therapeutic vitamin A supplements of greater than 10,000 units/day&#xD;
             (multivitamins are allowed).&#xD;
&#xD;
         13. Use of radiation therapy and/or anti-neoplastic agents within 90 days prior to Visit&#xD;
             1/Day 1 (Baseline).&#xD;
&#xD;
         14. Use within 30 days (1 month) prior to baseline or during the study of therapeutic&#xD;
             vitamin D supplement (daily multivitamins with total 800IU Vitamin D are allowed).&#xD;
&#xD;
         15. Use of medications known to exacerbate acne (Vitamin B12, lithium, corticosteroids;&#xD;
             Vitamin B12, etc. as part of a multivitamin regimen is allowed).&#xD;
&#xD;
         16. Start or change of dose of hormonal treatment (oral, implanted, topical contraceptives&#xD;
             and androgens) 3 months (90 days) prior to baseline or throughout the study. Use of&#xD;
             such therapy must remain constant during the study.&#xD;
&#xD;
         17. Use of medicated make-up throughout the study and significant change in the use of&#xD;
             consumer products within 30 days (1 month) of study entry and throughout the study&#xD;
             (other than study supplied cleanser and lotion).&#xD;
&#xD;
         18. Use within 30 days (1 month) prior to baseline or during the study of 1)&#xD;
             spironolactone, 2) systemic steroids*, 3) systemic (e.g., oral or injectable)&#xD;
             antibiotics, 4) systemic treatment for acne vulgaris (other than oral retinoids which&#xD;
             require a 6-month washout), or 5) immunosuppressive agents**. (*Intranasal and inhaled&#xD;
             corticosteroids do not require a washout and may be used throughout the study if at a&#xD;
             stable and standard dose.)** Subjects may use systemic anti-inflammatory agents (i.e.,&#xD;
             NSAIDs (Ibuprofen or Aspirin) for pain relief) as needed (with no more than 7 days of&#xD;
             consecutive use) throughout the study. Prophylactic use of low dose Aspirin 81 mg is&#xD;
             allowed. *** Subjects may use Acetaminophen for pain relief, as needed throughout the&#xD;
             study&#xD;
&#xD;
         19. Use within 14 days (2 weeks) prior to baseline or during the study of 1) topical&#xD;
             steroids, 2) topical retinoids, 3) topical anti-acne medications (e.g. Benzoyl&#xD;
             peroxide, retinoids, azelaic acid, α-hydroxy/glycolic acid, Clindamycin, etc.)&#xD;
             including OTC preparations 4) topical anti-inflammatory agents, or 5) topical&#xD;
             antibiotics.&#xD;
&#xD;
         20. Use on the face within 1 month (30 days) prior to baseline or during the study of 1)&#xD;
             cryodestruction or chemodestruction, 2) dermabrasion, 3) photodynamic therapy, 4) acne&#xD;
             surgery, 5) intralesional steroids, or 6) x-ray therapy.&#xD;
&#xD;
         21. Use of medicated cleansers (e.g. benzoyl peroxide, salicylic acid, sulfur or&#xD;
             triclosan) within 2 weeks (14 days) of study start and throughout the study.&#xD;
&#xD;
         22. Subject consumes excessive alcohol, abuses drugs, or has a condition that could&#xD;
             compromise the subject's ability to comply with study requirements.&#xD;
&#xD;
         23. Use of Antipruritics, including antihistamines within 24 hours (1day) of all study&#xD;
             visits (Visit 1 through Visit 4).&#xD;
&#xD;
         24. Participation in any clinical study involving an investigational product, agent or&#xD;
             device ( that might influence the intended effects or mask the side effects of study&#xD;
             medication ) in the 4 weeks (30 days) prior Visit 1/Day 1 (Baseline) or throughout the&#xD;
             study.&#xD;
&#xD;
         25. Previous enrollment in this study or current enrollment in this study at another&#xD;
             participating site.&#xD;
&#xD;
         26. Employee (or employee's family member) of the research center or private practice, or&#xD;
             subjects who have a conflict of interest.&#xD;
&#xD;
         27. Use of tanning booths, sun lamps, sunbathing or excessive exposure to the sun 1 week&#xD;
             (7 days) prior to enrollment and throughout the study.&#xD;
&#xD;
         28. Subjects who in the opinion of the investigator, are unlikely to be able to follow the&#xD;
             restrictions of the protocol and complete the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tennessee Clinical Research Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 31, 2015</study_first_submitted>
  <study_first_submitted_qc>August 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2015</study_first_posted>
  <results_first_submitted>October 21, 2020</results_first_submitted>
  <results_first_submitted_qc>October 22, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 16, 2020</results_first_posted>
  <disposition_first_submitted>June 27, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>June 27, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 29, 2016</disposition_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
    <mesh_term>Benzoyl Peroxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 12, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT02515305/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 12, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT02515305/SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Test Product</title>
          <description>Clindamycin and Benzoyl Peroxide Gel (combination)</description>
        </group>
        <group group_id="P2">
          <title>Reference Product</title>
          <description>Clindamycin and Benzoyl Peroxide Gel (Reference) (combination)</description>
        </group>
        <group group_id="P3">
          <title>Placebo Product</title>
          <description>Placebo gel (combination)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="385"/>
                <participants group_id="P2" count="378"/>
                <participants group_id="P3" count="127"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="356"/>
                <participants group_id="P2" count="343"/>
                <participants group_id="P3" count="113"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Test Product</title>
          <description>Clindamycin and Benzoyl Peroxide Gel (combination)</description>
        </group>
        <group group_id="B2">
          <title>Reference Product</title>
          <description>Clindamycin and Benzoyl Peroxide Gel (Reference) (combination)</description>
        </group>
        <group group_id="B3">
          <title>Placebo Product</title>
          <description>Placebo gel (combination)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="385"/>
            <count group_id="B2" value="378"/>
            <count group_id="B3" value="127"/>
            <count group_id="B4" value="890"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.1" spread="5.83"/>
                    <measurement group_id="B2" value="20.3" spread="6.07"/>
                    <measurement group_id="B3" value="18.9" spread="5.34"/>
                    <measurement group_id="B4" value="20.0" spread="5.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="216"/>
                    <measurement group_id="B2" value="213"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="491"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="169"/>
                    <measurement group_id="B2" value="165"/>
                    <measurement group_id="B3" value="65"/>
                    <measurement group_id="B4" value="399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="230"/>
                    <measurement group_id="B2" value="230"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="534"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="155"/>
                    <measurement group_id="B2" value="148"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="356"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="125"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="226"/>
                    <measurement group_id="B2" value="243"/>
                    <measurement group_id="B3" value="75"/>
                    <measurement group_id="B4" value="544"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Percent Change From Baseline in Inflammatory (Papules and Pustules) Lesions</title>
        <time_frame>Baseline to Day 84</time_frame>
        <population>per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Test Product</title>
            <description>Clindamycin and Benzoyl Peroxide Gel (combination)</description>
          </group>
          <group group_id="O2">
            <title>Reference Product</title>
            <description>Clindamycin and Benzoyl Peroxide Gel (Reference) (combination)</description>
          </group>
          <group group_id="O3">
            <title>Placebo Product</title>
            <description>Placebo gel (combination)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change From Baseline in Inflammatory (Papules and Pustules) Lesions</title>
          <population>per protocol population</population>
          <units>percentage of lesion change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="322"/>
                <count group_id="O2" value="316"/>
                <count group_id="O3" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.05" spread="29.823"/>
                    <measurement group_id="O2" value="72.84" spread="26.926"/>
                    <measurement group_id="O3" value="51.53" spread="28.403"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>provides 85% power of success</non_inferiority_desc>
            <param_type>equivalence ratio</param_type>
            <param_value>97.54</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94.6</ci_lower_limit>
            <ci_upper_limit>104.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Percent Change From Baseline in Non-inflammatory (Open and Closed Comedones) Lesions</title>
        <time_frame>Baseline to Day 84</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Test Product</title>
            <description>Clindamycin and Benzoyl Peroxide Gel (combination)</description>
          </group>
          <group group_id="O2">
            <title>Reference Product</title>
            <description>Clindamycin and Benzoyl Peroxide Gel (Reference) (combination)</description>
          </group>
          <group group_id="O3">
            <title>Placebo Product</title>
            <description>Placebo gel (combination)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change From Baseline in Non-inflammatory (Open and Closed Comedones) Lesions</title>
          <population>Per protocol population</population>
          <units>percentage of lesion change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="322"/>
                <count group_id="O2" value="316"/>
                <count group_id="O3" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.99" spread="30.032"/>
                    <measurement group_id="O2" value="58.93" spread="29.046"/>
                    <measurement group_id="O3" value="32.25" spread="41.322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>provides 85% power of success</non_inferiority_desc>
            <param_type>Equivalence ratio</param_type>
            <param_value>100.10</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96</ci_lower_limit>
            <ci_upper_limit>109.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>84 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Test Product</title>
          <description>Clindamycin and Benzoyl Peroxide Gel (combination)</description>
        </group>
        <group group_id="E2">
          <title>Reference Product</title>
          <description>Clindamycin and Benzoyl Peroxide Gel (Reference) (combination)</description>
        </group>
        <group group_id="E3">
          <title>Placebo Product</title>
          <description>Placebo gel (combination)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jonathan Schwartz</name_or_title>
      <organization>Perrigo</organization>
      <phone>718-960-9900</phone>
      <email>jonathan.schwartz@perrigo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

